| References: |
CPI-169, a representative compound from that effort, inhibits the catalytic activity of PRC2 with an IC50 of < 1nM, decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. Importantly, compound treatment triggers a sequence of downstream functional consequences of EZH2 inhibition whereby apoptosis is not induced before ten days of continuous target engagement For the detailed information of CPI-169 (R), the solubility of CPI-169 (R) in water, the solubility of CPI-169 (R) in DMSO, the solubility of CPI-169 (R) in PBS buffer, the animal experiment (test) of CPI-169 (R), the cell expriment (test) of CPI-169 (R), the in vivo, in vitro and clinical trial test of CPI-169 (R), the EC50, IC50,and affinity,of CPI-169 (R), Please contact DC Chemicals. |
